There are a number of options for treatment following on from anti-TNF therapy, however there is currently no clear rationale for deciding which treatment is superior in patients who have initially failed anti-TNF therapy. This study aims to investigate whether the choice of drug treatment may be influenced by different cell types in synovial tissue (tissue which lines joints and becomes inflamed in people with RA). This will hopefully provide evidence for stratifying patients into different treatment groups following anti-TNF therapy. The ultimate aim is to provide a tailored approach to treatment decisions in patients at this stage of their disease, in order to maximise their potential to respond to therapy.
It is clear that a “one size fits all” strategy does not work when choosing the most effective drug for ongoing treatment of RA in patients for whom conventional disease-modifying anti-rheumatic drugs (DMARDs) have failed. In this trial, we will be investigating three biologic drugs called Etanercept, Rituximab and Tocilizumab. The aim of this trial is to investigate whether the most effective choice of drug treatment may be predicted by different cell types in synovial tissue, which lines joints and becomes inflamed in people with RA. Click here for more information.
BSRBR-RA and BRAGGS are two interlinked studies. Participants take part in one or both of these studies. The BSRBR-RA study is an observational study which aims to assess whether some of the new treatments used in the treatment of rheumatic conditions have a greater risk of serious side effects and long term health problems than established treatments. Whereas, the BRAGGS study looks at whether clinical, serological, genetic and psychological factors influence arthritis, or the body’s response to treatment.
In collaboration with Abbvie, we have established an international multicentre trial, the Targeted Ultrasound in Rheumatoid Arthritis (TURA) study. Thirteen sites have been initiated across eight countries to recruit 400 patients to investigate ultrasound detected synovitis as a primary determinant for treatment escalation.
This is an observational study of patients who have just received an arthritis diagnosis which investigates issues that determine remission and progression of the condition.